Efficacy of bevacizumab in combination with irinotecan or oxaliplatin as 2nd and 3rd or later-line treatment in metastatic colorectal cancer (MCRC) patients

被引：0
|
作者：
Samalin, E.
Lievre, A.
Boyer-Gestin, C.
Mitry, E.
Senesse, P.
Lepere, C.
Bachet, J.
Vaillant, J.
Rougier, J.
Ychou, M.
机构：
[1] Ccentre Aurelle, Montpellier, France
[2] Hop Ambroise Pare, Boulogne Billancourt, France
来源：
ANNALS OF ONCOLOGY | 2007年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：VII30 / VII30
页数：1
相关论文
共 50 条
  • [31] Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
    Yang, Qiong
    Yin, Chenxi
    Liao, Fangxin
    Huang, Yuanyuan
    He, Wenzhuo
    Jiang, Chang
    Guo, Guifang
    Zhang, Bei
    Xia, Liangping
    ONCOTARGETS AND THERAPY, 2015, 8 : 2407 - 2413
  • [32] Phase II Study of Irinotecan, Trifluridine/tipiracil (TAS-102) plus Bevacizumab as a Later-line Therapy for Patients with Metastatic Colorectal Cancer (mCRC): a prospective single-center explorative study
    Li, Baoqi
    Yang, Wenwei
    Liu, Na
    Bi, Deying
    Yang, Tingting
    Wu, Guifu
    Sun, Yongkun
    BRITISH JOURNAL OF CANCER, 2024, 131 (11) : 1775 - 1780
  • [33] Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial
    Masi, Gianluca
    Loupakis, Fotios
    Salvatore, Lisa
    Fornaro, Lorenzo
    Cremolini, Chiara
    Cupini, Samanta
    Ciarlo, Andrea
    Del Monte, Francesca
    Cortesi, Enrico
    Amoroso, Domenico
    Granetto, Cristina
    Fontanini, Gabriella
    Sensi, Elisa
    Lupi, Cristiana
    Andreuccetti, Michele
    Falcone, Alfredo
    LANCET ONCOLOGY, 2010, 11 (09): : 845 - 852
  • [34] Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.
    Sobrero, A.
    Ackland, S.
    Carrion, R. P.
    Chiara, S.
    Clarke, S.
    Giron, C. G.
    Langer, B.
    Zurlo, A.
    Young, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
  • [35] Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer
    Grapsa, Dimitra
    Syrigos, Konstantinos
    Saif, Muhammad Wasif
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (11) : 1267 - 1281
  • [36] First-line treatment of metastatic colorectal cancer (MCRC) with FOLFOXIRI (irinotecan, oxaliplatin and infusional 5FU/LV) in combination with bevacizumab (BV): A phase II study by the GONO group
    Masi, G.
    Loupakis, F.
    Baldi, G.
    Fornaro, L.
    Stasi, I
    Vasile, E.
    Cialo, A.
    Cavaciocchi, D.
    Di Leo, A.
    Puglisi, M.
    Ciprotti, M.
    Amoroso, D.
    Fea, E.
    Di Donato, S.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 26 - 26
  • [37] FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the GONO group
    Falcone, A.
    Masi, G.
    Loupakis, F.
    Vasile, E.
    Ciarlo, A.
    Cavaciocchi, D.
    Amoroso, D.
    Puglisi, M.
    Fea, E.
    Brunetti, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Salvatore, L.
    Fornaro, L.
    Baldi, G.
    Stasi, I
    Cupini, S.
    Ciarlo, A.
    Del Monte, F.
    Trenta, P.
    Mezi, S.
    Rondini, M.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [39] Clinical impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib or trifluridine/tipiracil as later-line
    Nakajima, Hiromichi
    Fukuoka, Shota
    Moriwaki, Toshikazu
    Masuishi, Toshiki
    Takashima, Atsuo
    Kumekawa, Yosuke
    Kajiwara, Takeshi
    Yamazaki, Kentaro
    Komoda, Masato
    Makiyama, Akitaka
    Denda, Tadamichi
    Hatachi, Yukimasa
    Suto, Takeshi
    Sugimoto, Naotoshi
    Enomoto, Masanobu
    Ishikawa, Toshiaki
    Kashiwada, Tomomi
    Oki, Eiji
    Gosho, Masahiko
    Shimada, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [40] CHRONOCHEMOTHERAPY (CCT) WITH FLUOROURACIL, OXALIPLATIN, IRINOTECAN,, FOLINIC ACID (FOLFOXIRI)± BEVACIZUMAB (BEV) IN METASTATIC COLORECTAL CANCER (MCRC): A PHASE 2 TRIAL
    Tumolo, Salvatore
    Boccalon, Massimo
    Marzano, Bernardo
    Fanti, Gianni
    Scata, Armando
    Santeufemia, Davide Adriano
    Del Conte, Alessandro
    Chiara, Giordano
    Tosolini, Giancarlo
    Marus, Walli
    Sulfaro, Sandro
    ANNALS OF ONCOLOGY, 2009, 20
12345